Imaging of complications from hematopoietic stem cell transplant

Tarun Pandey, Suresh Maximin¹, Puneet Bhargava¹

Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, ¹Department of Radiology, University of Washington and VA Puget Sound Health Care System, Seattle, Washington, USA

Correspondence: Dr. Tarun Pandey, University of Arkansas for Medical Sciences, 4301, West Markham Street, Slot # 556, Little Rock, Arkansas, 72205, USA. E-mail: drtarunpandey@gmail.com

Abstract

Stem cell transplant has been the focus of clinical research for a long time given its potential to treat several incurable diseases like hematological malignancies, diabetes mellitus, and neuro-degenerative disorders like Parkinson disease. Hematopoietic stem cell transplantation (HSCT) is the oldest and most widely used technique of stem cell transplant. HSCT has not only been used to treat hematological disorders including hematological malignancies, but has also been found useful in treatment of genetic, immunological, and solid tumors like neuroblastoma, lymphoma, and germ cell tumors. In spite of the rapid advances in stem cell technology, success rate with this technique has not been universal and many complications have also been seen with this form of therapy. The key to a successful HSCT therapy lies in early diagnosis and effective management of complications associated with this treatment. Our article aims to review the role of imaging in diagnosis and management of stem cell transplant complications associated with HSCT.

Key words: Complications; hematopoietic stem cell; imaging; intervention; radiology; stem cell

Stem Cell Types: Definitions and Classification

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can undergo mitosis to produce more stem cells. A stem cell is characterized by two essential properties: Power of self-renewal through infinite cycles of cell divisions and capacity to differentiate into specialized cells (also called as potency). While all stem cells have a capacity of self-renewal, not all stem cells are equal in terms of potency. Several lineages of stem cells can be found. The embryonic and adult stem cells are totipotent or omnipotent, allowing them to give rise to any mature cell type. This latter property implies that an entire organism can be constructed from these embryonic stem cells. Multipotent cells can differentiate into a number of cell types, but these are closely related family of cells. Oligopotent cells are further limited to differentiate into only a few cell types (e.g. lymphoid or myeloid cells), whereas unipotent cells can only produce one cell line. It is important to note that the property of self-renewal in stem cells is unlimited. This differentiates them from other non-stem cells like progenitor cells that have a limited capacity of self-renewal. Also, while the stem cells maintain the power of self-renewal, non-stem cells can divide only a limited number of times and are “committed” to differentiate into their respective “target cells.”

Based on their source, stem cells can be classified into two broad categories: Embryonic stem cells, found in the inner mass of the blastocyst, and adult stem cells, found in various mammalian tissues. Figure 1 presents a simplified representation of the stem cells and their lineages in the body.

Stem Cell Transplant: Current Status and Applications

Autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is now a routine procedure and has
been successfully used for treatment of various hematological conditions such as lymphoma, multiple myeloma, leukemia, anemias, and solid tumors like neuroblastoma and germ cell tumors. Also, selected autoimmune conditions like systemic lupus erythematosus have also been treated using stem cells. According to estimates, more than 50,000 autologous or allogenic transplantation procedures are performed every year worldwide.[1]

Continued research in this area has now made it possible to produce a stem cell from almost any other human cell instead of using embryos.[2] This has alleviated some of the ethical concerns and has created more opportunities in the use of stem cells for tissue repair and regeneration.

Recently, stem cells have been successfully used in treatment of non-hematological conditions in humans with successful cartilage regeneration in human knee using autologous adult mesenchymal stem cells.[3] Subsequently, promising results in a human clinical trial in treating type 1 diabetes mellitus has been shown using cord blood-derived multipotent stem cells (CB-SCs).[4]

Complications in HSCT: Basic concepts
A clear understanding of the stem cell immunophysiology is imperative before attempting to study the complications associated with HSCT. The HSCT therapy is intended to completely or partially replace the recipient’s existing diseased hematopoietic system. This process necessitates ablation of the recipient's bone marrow and tumor cells, which usually entails use of high-dose chemotherapy and/or total body irradiation. After this “conditioning regimen,” stem cells are transfused to restore and repopulate the patient’s marrow.

Transplantation of stem cells has been associated with a myriad of systemic complications ranging from infection, graft versus host disease (GVHD), and neoplasia, predominantly due to the immunosuppression associated with stem cell transplantation. These complications follow a predictable pattern in that recipients of allogenic transplant are at risk for developing GVHD and those receiving autologous transplant, though not at risk of GVHD, have more chances of developing infections or relapse of the disease.

After HSCT, the prognosis of the patient (or development of complications) depends on several factors. From the preceding discussion, it is apparent that the type of transplantation, whether allogenic, autologous, or syngeneic, plays a vital role. The potency of the conditioning regimen is another important prognostic factor, wherein it determines how much residual disease is present at the time of transplantation. Other factors include patient’s age and the underlying disease condition. In general, prognosis is poorer in adults, those with autologous transplant, and in whom residual disease was present.[5]

Imaging of stem cell transplant complications
Complications can manifest in almost all organ systems of the body and follow a predictable temporal sequence that mirrors the periods of immunosuppression and recovery following transplantation. In general, there are three phases following transplantation: Pre-engraftment phase (0-30 days post-transplant), early post-transplantation phase (30-100 days post-transplant), and late post-transplant phase (>100 days post-transplant).[6] Figure 2 lists the location, relative frequency, and temporal course of complications following HSCT.

Pulmonary complications
Pulmonary complications are the most frequent of all stem cell transplant complications, occurring in approximately 40-60% patients.[7] These complications are best evaluated using high-resolution computed tomography (HRCT) due to its increased sensitivity and specificity in diagnosis and management of both infectious and non-infectious conditions.[8] However, a pattern-based differential
diagnosis is possible based only on chest radiograph findings [Figure 3].

Early complications
Pre-engraftment phase
A variety of complications can occur in the early pre-engraftment phase. Early recognition and prompt treatment is important to prevent morbidity and mortality. However, it should be noted that imaging findings are not specific in many cases, and in the majority of cases, empiric treatment is started based on clinical suspicion. For example, bacterial infection, drug toxicity, and diffuse pulmonary hemorrhage may manifest as consolidation and air-space opacities. In this situation, the role of imaging is twofold. Early detection of the abnormality on CT or radiographs may show abnormality when the clinical abnormalities are nonspecific. The other application of imaging is differentiation of fungal infections from other complications. Most fungal infections produce nodular infiltrates, nodules, or masses. While not definitive, this finding can help in directing appropriate treatment. Developing a pattern approach and knowledge of timeline of complications is most helpful in such situations [Figures 2 and 3].

Lung infections
These mostly occur later in the course of the transplant, but are not infrequent early on; approximately 35% of HSCT cases present with lung infection. Overall, there is a trend for non-infectious versus infectious complications, given the widespread use of antibiotics. However, in the pre-engraftment phase, both infectious and non-infectious complications can occur with equal frequency. Fungal infections manifest more often because most patients who are febrile receive empiric antibiotics for assumed bacterial infections, giving mostly negative cultures. As much as 50% of all pulmonary infections in the allogenic stem cell transplant setting are fungal in origin.

Fungal pneumonia
Aspergillus fumigatus is the most common fungal agent seen in the setting of HSCT. It is most commonly seen in the early pre-engraftment phase, but can also occur in the post-engraftment and late phases [Figure 4]. Others including Candida albicans, Fusarium, Zygomycosis (Mucor and Rhizopus), Nocardia, and Cryptococcus are less common. The risk factors, prevalence, and key radiological findings of these fungal infections are summarized in Table 1.

Pulmonary edema
This is not uncommon in a post-transplant setting.

Table 1: Summary of different fungal infections of the lungs encountered in patients with hematopoietic stem cell transplantation

|                  | Aspergillus | Candida | Zygomycosis | Cryptococcus |
|------------------|-------------|---------|-------------|--------------|
| Risk factor      | Neutropenia, steroid treatment for GVHD | Indwelling venous catheter | Increased use of triazole antifungals for Aspergillus infections | Neutropenia, steroid treatment for GVHD |
| Prevalence       | 10-15%      | 11%     | 1-2%        | Not known |
| Radiological findings | Multiple masses, nodules, or air-space opacities; upper lobe; halo sign; tracheobronchial disease | Multiple poorly defined or miliary nodules; halo sign | Angio-invasive disease similar to Aspergillus; lung infarction; halo sign; cavitation | Solitary or multiple nodules; cavitation |
| Course of disease/prognosis | Cavitary, air crescent indicates good prognosis | Rapid-onset clinical disease | Includes Mucor and Rhizopus; high mortality (80%) | Can be associated with neurological symptoms |

GVHD = Graft versus host disease
Other than the routine hydrostatic, cardiac, and renal conditions leading to pulmonary edema, some unique causes relate to drug-induced toxicity, sepsis, transfusion, and intravenous (IV) fluid overload. Pulmonary edema is typically diagnosed based on clinical findings and confirmed radiographically. Engraftment syndrome can be confused with pulmonary edema. This condition is characterized by fever, erythematous rash, and non-cardiogenic pulmonary edema, and usually occurs at the time of neutrophil recovery. Imaging may be normal or show nonspecific findings like ground-glass opacities, hilar/peribronchial air-space consolidations, septal thickening, and effusions that can mimic pulmonary edema, infections, or GVHD.

Diffuse alveolar hemorrhage
Diffuse alveolar hemorrhage (DAH) is a relatively rare complication seen in approximately 2-20% cases. Though rare, it can be life-threatening. Prompt diagnosis and treatment with steroids has shown favorable outcome; hence, awareness of clinical and radiological findings is helpful. In spite of alveolar hemorrhage, gross hemoptysis is rare. The majority of patients with DAH present with tachypnea and dyspnea. It can rapidly progress usually within the first 2 weeks of HSCT. Radiographic findings may precede the development of symptoms by several days, but show nonspecific patchy alveolar infiltrates that become more confluent and show central, mid, and lower lung zone predominance. Diagnosis is established on bronchoalveolar lavage that shows progressive bloodier aliquots of lavage fluid.

Treatment-related toxicity
Lung injury can also result from total body irradiation or chemotherapy with lung toxicity (Carmustine/methotrexate) in the immediate post-transplant period. Chemotherapy and radiation have synergistic risk of producing lung damage. Both imaging and biopsy findings are nonspecific. Imaging may show a pattern similar to acute respiratory distress syndrome (ARDS), hypersensitivity pneumonitis, and organizing pneumonia. Biopsy may show diffuse alveolar damage, histological equivalent of ARDS, type II alveolar epithelial cell atypia and hyperplasia, interstitial pneumonitis, and fibrosis. It is a diagnosis of exclusion.

Early post-transplant phase complications (days 31-100)
Pneumonia remains the most common complication in this period, though less common compared to the pre-engraftment phase. This is due to gradual resolution of severe neutropenia by day 100. Effects of induction chemotherapy and radiation also show healing response during this period. However, due to several factors like T-cell dysfunction, hypogammaglobulinemia, diminished phagocyte function, acute GVHD, and use of immunosuppressant to manage the GVHD, the patient becomes susceptible to multiple infections. Acute GVHD and idiopathic pneumonia are the other non-infectious complications in this period.

Lung infection
Overall, viral [cytomegalovirus (CMV), adenovirus] and fungal infections (Pneumocystis jiroveci, Aspergillus) are more common than bacterial infections. Due to effective prophylaxis, P. jiroveci is rare. Among the bacterial infections, Staphylococcus may be seen in patients with indwelling central line. The patients are also prone to infections with encapsulated bacteria like Streptococcus pneumonia and Haemophilus influenzae.

CMV infection
Most CMV infections result from reactivation of the latent virus in seropositive recipients from the peripheral blood leukocytes or as primary infection from a seropositive donor. CMV infection not only manifests as pneumonia but can also cause hepatitis and colitis. CMV pneumonia carries 15-20% mortality with a high case-fatality rate of 80-90%. Chest radiographs may be normal, but typically show patchy areas of ground glass or consolidation. HRCT may show ground-glass opacities, air-space consolidations, or small (<5 mm) centrilobular nodules. Other respiratory and enteric viruses (respiratory syncytial virus, RSV and adenovirus) may either produce no radiological findings or may show diffuse ground-glass opacities.

P. jiroveci
It is rare in patients who receive prophylaxis. Chest radiographs can be normal early on or show reticulonodular infiltrates that progress to air-space consolidations. In cases when radiographs are negative, HRCT may show the characteristic ground-glass opacities and/or consolidations, either diffuse or perihilar in distribution. Sparing of the secondary pulmonary lobules has been described on HRCT. Other features include focal opacities, cavitations/pneumatoceles, or air cysts.

Figure 5 (A and B): CMV pneumonia after allogenic transplant. (A) Coronal CT image shows the nonspecific halo sign (nodules surrounded by ground-glass opacity) as well as centrilobular nodules (arrows). (B) Coronal CT image from another patient demonstrates scattered basilar predominant centrilobular nodules (black box). [Window Width 1500 HU, Window Level -600 HU]
Idiopathic pneumonia syndrome
It is the most common cause of diffuse radiographic abnormalities between 30 and 180 days after transplantation.[17] Idiopathic pneumonia syndrome (IPS) is a group of disorders that show common pathological findings of interstitial pneumonitis and/or diffuse alveolar damage. To make a diagnosis of IPS, two main criteria should be fulfilled. There should be widespread alveolar injury and absence of lower respiratory tract infection.[18]

- Widespread alveolar injury: It is defined as signs and symptoms of pneumonia, multilobar opacities on chest radiograph or CT scan, and evidence of abnormal pulmonary physiology manifested by an increased alveolar-arterial oxygen gradient or the need for supplemental oxygen
- Absence of lower respiratory tract infection, as determined by a negative bronchoalveolar lavage or lung biopsy, ideally followed by a second negative invasive test within 2 weeks.

The etiopathogenesis of IPS is not known, but studies have found an association between increasing incidence of IPS and aggressive preparative chemotherapy and radiation regimen before stem cell transplantation.[19] There is no optimal therapy for IPS. High-dose glucocorticoids have been tried, but overall prognosis is poor with 70-85% mortality.

Radiologically, nonspecific bilateral air-space opacities and consolidations with basilar predominance are seen, similar to non-cardiogenic pulmonary edema.

Late complications
Late post-transplant phase (>100 days after transplant)
This period is characterized by the recovery of host cell mediated and humoral immunity. The main complication during this phase is chronic GVHD, which is a reaction of donor T cells and natural killer (NK) cells to host antigens, treating them as foreign. While rare in autologous HSCT, it can be seen in 40-80% cases of allogenic transplants. Ironically, it needs immunosuppressive medications for both prophylaxis and treatment, halting the recovery of the host immunity. Hence, this phase continues until the stem cell recipient stops all immunosuppressive medications for GVHD, which is approximately 18-36 months post-transplantation. Radiologically, chronic GVHD manifests as bronchiolitis obliterans (BO) and cryptogenic organizing pneumonia.

Lung infections
If it were not for the chronic GVHD, infection is unusual in this period. Most infections are localized to the skin, the upper respiratory tract, and the lungs due to loss of skin and mucosal barriers. Viral infections, especially secondary to varicella zoster virus (VZV), are responsible for more than 40% of infections during this phase, bacteria are responsible for approximately 33%, and fungi cause approximately 20% infections.[14] The infections have similar radiological manifestations as discussed previously.

Bronchiolitis obliterans
While mild airflow obstruction and decrements in lung function are common following HSCT, moderate-to-severe airflow obstruction indicates the presence of BO. It has a strong association with chronic GVHD.[20] It can mimic infection and cryptogenic organizing pneumonia during this period; however, absence of fever and lung abnormalities on chest radiographs helps in distinguishing these conditions. The diagnosis of BO is established on pulmonary function tests showing reduced forced expiratory volume in 1 sec (FEV1). HRCT shows expiratory air trapping, mosaic attenuation, and bronchiolectasis. The airflow obstruction is non-reversible and is characterized by intraluminal fibrosis on histology [Figure 7].

Cryptogenic organizing pneumonia
Also called as bronchiolitis obliterans organizing pneumonia or BOOP, it can be due to various causes in post-HSCT setting. Apart from chronic GVHD, it may be related to lung irradiation, following CMV pneumonitis, or may be idiopathic.[21] Histologically, it is characterized by polypoid granulation tissue in the lumina of bronchioles and alveolar ducts, associated with a variable amount of interstitial and air-space mononuclear cell infiltration. HRCT may show bilateral, peripheral, and basilar predominant patchy air-space consolidation, randomly distributed ground-glass opacities, and bronchial wall thickening with dilatation, also described as the open bronchus sign [Figure 8].

Hepatic complications
Acute GVHD of the liver, drug-induced hepatotoxicity, and viral hepatitis are the top three causes of liver disease in HSCT patients. Other notable complications include hepatic sinusoidal obstruction syndrome (SOS) and liver infections.[22]

Acute GVHD of the liver
This is the most common hepatic complication following HSCT. Liver involvement is rarely in isolation, and
is frequently seen with cutaneous and/or acute gastrointestinal (GI) GVHD. Hepatic involvement manifests by rising conjugated bilirubin and alkaline phosphatase that are nonspecific and can be seen in hepatic SOS, viral hepatitis, and drug toxicity. Presence of a rash concurrent with the liver function abnormalities is suggestive of the diagnosis, but liver biopsy is required for confirming damage to the bile canaliculi (bile duct atypia and degeneration, epithelial cell dropout, lymphocytic infiltration of small bile ducts). Imaging findings are not sensitive or specific, but may show temporary dilatation and fluctuation in size of the common bile duct correlating with serum bilirubin concentration.\(^{[23]}\)

**Liver infections**

**Viral hepatitis**
The impaired cellular immunity post-HSCT can lead to reactivation of latent hepatitis B virus (HBV) that can result in fulminant hepatic failure. This warrants HBV vaccination to those patients who are hepatitis B surface antigen (HBsAg) negative and prophylactic antiviral therapy for those who are HBsAg positive. Unlike HBV, infection with hepatitis C virus (HCV) does not result in acute or fulminant disease. However, in the long term, it is a risk factor for hepatic veno-occlusive disease and GVHD. Imaging does not have much role to play in the diagnosis and management of viral hepatitis other than ruling out other confounding complications like infection or SOS.

**Liver abscess**
These can be bacterial or fungal in origin. Amongst the fungal infections, hepatosplenic candidiasis is very common. Imaging appearance of fungal infection varies according to the stages of its evolution and presence or absence of neutropenia. During the active phase, the lesion is predominantly hypoechoic on (US) with or without characteristic halo, bull’s eye, or wagon wheel appearance. The lesion becomes echogenic in the late phase. On CT and magnetic resonance imaging (MRI), similar phases have been described\(^{[24,25]}\) [Figure 9]. It is important to note that fungal lesions may not be visible until the patient recovers from the neutropenic stage. As neutropenia improves, the host mounts a response against the infection, imparting the characteristic halo and enhancement that makes them conspicuous. In a setting of neutropenia, MRI may be more sensitive than CT or US in detecting fungal micro-abscesses, given its increased contrast resolution. In cases when the initial scan is negative and there is a strong clinical suspicion for fungal infection, repeat imaging in 2 weeks may be performed.

**Hepatic SOS**
This was earlier called hepatic veno-occlusive disease and clinically even mimics Budd-Chiari syndrome. However, it is now known to result from endothelial damage to the hepatic sinusoids causing fibrosis and occlusion of the hepatic outflow. The hepatic veins and inferior vena cava remain patent.\(^{[26]}\) SOS is not unique to HSCT and can be induced by the ingestion of pyrrolizidine alkaloids, like herbal tea, high-dose (>30 Gy) radiation therapy to the liver, radio-embolization of liver tumors, and after liver transplantation. It has a prevalence of 14% (5-60%) post-HSCT. No single factor is implicated in its causation. Pre-existing liver disease, aggressive conditioning therapy, young age, and poor baseline performance status of the host are the risk factors for SOS.\(^{[27]}\) Diagnostic criteria have been defined that rely on the clinical findings and lab abnormalities. According to
the modified Seattle criteria, hepatic SOS is diagnosed by occurrence of two or more of the following events within 20 days of HCT: [28]
- Serum total bilirubin >2 mg/dl
- Hepatomegaly or right upper quadrant pain
- Sudden weight gain >2% of baseline body weight (due to fluid accumulation).

US imaging is sensitive in detecting ascites, hepatosplonemegaly, portal vein enlargement, marked gallbladder wall edema, and abnormal Doppler parameters (portal venous pulsatility, hepatofugal portal venous flow, increased hepatic artery resistive index >0.8, and loss of triphasic flow pattern in the hepatic veins) [Figure 10]. However, US findings are nonspecific and similar findings can be seen in patients with absence of SOS. Studies have shown that no US finding is strongly associated with veno-occlusive disease (VOD). [29] Imaging may help in differential diagnosis. For example, the clinical findings of SOS are indistinguishable from those of acute Budd-Chiari syndrome. Doppler ultrasound, CT, or MRI can noninvasively show the thrombosis of hepatic veins and/or intrahepatic or suprahepatic vena cava, differentiating it from SOS where the hepatic venous outflow obstruction is at the level of the sinusoids and terminal hepatic venules. This distinction may be critical as untreated SOS is associated with significant mortality and morbidity. Unlike Budd-Chiari syndrome, anticoagulation with heparin has not proved to be beneficial. Most patients are treated symptomatically with sodium and fluid restriction along with diuretic therapy. Similarly, imaging can be useful to distinguish SOS from hepatic GVHD, another potential mimic in this setting. CT findings of periportal edema, ascites, and narrowed right hepatic vein have been shown to be associated with SOS more than GVHD. [30] It is important to note that this distinction is not entirely reliable and final diagnosis may require biopsy. Table 2 summarizes the salient features of hepatic SOS, GVHD, and Budd-Chiari syndrome.

Table 2: Summary of salient liver complications after hematopoietic stem cell transplant

| Sinusoidal obstruction syndrome | Budd-Chiari syndrome | Acute GVHD |
|--------------------------------|----------------------|------------|
| Risk factors/etiologies        | Endothelial injury is the result of conditioning regimen in stem cell transplant | Polycythemia, pregnancy, post-partum, oral contraceptives, HCC | Allogenic stem cell transplant |
| Pathology                      | Endothelial damage to the hepatic sinusoids causing fibrosis/occlusion of the hepatic outflow | Intraluminal or extraluminal obstruction of hepatic veins due to thrombus or extrinsic compression | Damage to bile canaliculi with degeneration and lymphocytic infiltration |
| Clinical features              | Weight gain, tender hepatomegaly, increased bilirubin, ascites | Pain, jaundice, hepatomegaly, ascites, liver dysfunction | Rash |
| Imaging                        | US: Ascites, hepatosplonemegaly, PV enlargement, gallbladder wall edema, abnormal Doppler parameters | Thrombus will differentiate from SOS Ascites, hepatosplonemegaly, decreased/absent hepatic vein flow | Liver function abnormal, elevated bilirubin and alkaline phosphatase Associated GI and skin findings |
| Treatment                      | Sodium/fluid restriction, diuretics, Anticoagulation of no use | Sodium/fluid restriction, diuretics, anticoagulation | Temporary fluctuation in size of CBD correlating with changes in serum bilirubin |

GVHD: Graft versus host disease, SOS: Sinusoidal obstruction syndrome, CBD: Common bile duct, PV: Portal vein, US: Ultrasonography, HCC: Hepatocellular cancer

Bowel complications
Several bowel complications can be seen in the post-HSCT setting like CMV enterocolitis, Clostridium difficile infection, or chemoradiation toxicity. However, by far, acute GVHD is the most common complication.

GI tract GVHD
GI tract is one of the most commonly affected target sites of acute GVHD (74%), the other sites being the skin (70%) and liver (44%). [31] GVHD is classified based on clinical features and timing of presentation. The acute and chronic forms of the disease have mutually exclusive features forming opposite ends of the spectrum with an intermediate form having features of both acute and chronic GVHD. Clinically, acute GVHD presents with a maculopapular rash, symptoms of GI upset like nausea, vomiting, diarrhea, and a rising serum bilirubin concentration. In contrast, patients with chronic GVHD commonly demonstrate skin involvement...
resembling lichen planus or the cutaneous manifestations of scleroderma; dry oral mucosa with ulcerations and sclerosis of the GI tract. Radiological findings are not diagnostic of GVHD. Upper GI tract involvement is best evaluated on endoscopy and biopsy of the involved mucosa showing mucosal erythema, denudation, and aphthous ulcers. An important caveat is that visually normal mucosa does not rule out GVHD. Hence, histological evaluation is necessary. Lower GI involvement can also be easily established on rectal biopsy with high sensitivity.[32] For noninvasive evaluation of bowel involvement, contrast-enhanced CT with negative oral contrast (water) should be performed to show mucosal hyperemia and “halo sign” [Figure 11]. Fluid-distended bowel loops with thickened walls may be seen. However, these findings are nonspecific and may be seen with infectious enterocolitis, radiation enteritis, and drug-induced or neutropenic colitis (typhlitis).

Other GI complications
Other infectious and non-infectious complications can mimic GVHD. Some CT findings may be helpful in differentiation of these entities. For example, neutropenic enterocolitis commonly involves the ascending colon, especially cecum. There is a higher incidence of pneumatosis, mesenteric stranding, and ascites with neutropenic colitis, compared to acute GVHD. Bowel mucosal enhancement and dilatation are more common in GVHD. Both CMV and *C. difficile* colitis can present with pancolitis with marked colonic wall thickening and nodularity [Figures 12 and 13]. Hence, selective staining of such pathogens should be performed on the biopsy specimens. Occasionally, pneumatosis intestinalis may be seen as air outlining the bowel wall. In many cases, it is benign due to mucosal defects from steroid-induced hypertrophy of the Peyer’s patches. The appearance can be dramatic with extensive mesenteric, portal venous gas and frank pneumoperitoneum. This “benign pneumatosis intestinalis” resolves on its own with conservative management; however, it needs to be differentiated from CMV or typhlitis-related pneumatosis where it implies imminent bowel perforation.[33]

Genitourinary complications
Renal functional impairment
It is defined as sustained decrease in glomerular filtration rate below 60 ml/min/1.73 m² and can be seen in up to 65% cases in long-term allograft survivors post-HSCT. The etiology of renal functional impairment can be multifactorial, including membranous glomerulopathy and other autoimmune-like diseases of the glomerulus that have been associated with chronic GVHD. No specific imaging findings are seen.

Hemorrhagic cystitis
It is a well-known complication of HSCT. It is mostly due to two viruses, adenovirus and BK virus. On CT and US, focal
or diffuse bladder wall thickening may be seen [Figure 14]. There may be intraluminal hematoma or sloughed mucosa.

Two forms of cystitis have been reported. Pre-engraftment cystitis, a milder and transient form, is seen in the first few days of transplantation and responds to supportive therapy, whereas post-engraftment cystitis that occurs 1-2 months following transplantation is protracted, and is associated with severe GVHD and may require surgical intervention.

Renal parenchymal infections
Renal abscesses secondary to bacterial and fungal infections are also common following transplantation. The appearance is similar to infections in other solid organs [Figure 15]. Most infections occur early in the transplant period.

Central nervous system and head-neck complications
CNS infections
Like other systems, the risk of infection and the types of organism that invade the CNS depend on the duration after HSCT and the level of immune impairment. For example, in the early pre-engraftment period, profound neutropenia predisposes to gram-negative bacterial, viral, and fungal pathogens. In the post-engraftment period, CMV, fungal, and gram-positive infections are encountered; in the late post-engraftment period, infections from encapsulated bacteria and herpes zoster virus are common due to impaired humoral immunity. Bacterial infections are rarely manifested due to routine prophylaxis. Amongst the fungal infections, Mucor and Aspergillus are common, with Aspergillus being the overall most common cause of focal infective brain lesion after stem cell transplantation. While bacterial and fungal abscesses are seen as single or multiple focal lesions on CT or MRI, Mucor is typically an aggressive infection that occludes vessels and can invade the brain parenchyma [Figure 16]. Herpes also causes an encephalitis pattern, with characteristic temporal lobe involvement.

Other CNS complications
Several other CNS complications can be seen like intra or axial hematomas and infarction that have similar imaging appearance to those seen in the general population. Posterior reversible encephalopathy syndrome (PRES) is a potentially reversible condition thought to result from pre-transplantation conditioning and GVHD prophylaxis. It typically occurs within 1 month of initiation of therapy and is manifested as visual disturbances, cerebellar ataxia, confusion, and seizures. CT and MRI reveal abnormalities in the gray and white matter of occipital, parietal, posterior temporal, and frontal lobes [Figure 17].

Musculoskeletal complications
Osteoporosis and avascular necrosis are the most frequently encountered complications of the musculoskeletal system. Osteoporosis typically occurs early after HSCT, but does show favorable response to bisphosphonate treatment. Avascular necrosis or bone infarction occurs in approximately 5-20% cases following HSCT. The imaging appearance of bone infarction and avascular necrosis is the same as in general population without HSCT. Osteomyelitis is a rare complication following HSCT, but can be lethal and requires aggressive management, frequently with a combination of drugs. Cases of bacterial and fungal osteomyelitis have been reported following HSCT.

Figure 14: Post-engraftment cystitis in 2 months after transplant. Axial contrast-enhanced CT image demonstrates diffuse urinary bladder wall thickening (arrow)

Figure 15: Fungal microabscesses and pyelonephritis 2 weeks after transplant. Coronal contrast-enhanced CT demonstrates bilateral striated nephrogram and discrete small low attenuation foci (arrows)
Secondary malignancies
Several secondary malignancies can be seen in patients who have undergone HSCT, occurring at different time periods following transplant. Three different types of malignancies are seen: Solid tumors, hematological malignancies, and post-transplant lymphoproliferative disorder (PTLD). Solid tumors and hematological malignancies typically occur late in the post-transplant course (>3 years), and PTLD usually occurs in the first year after transplantation.[39] This review will focus on PTLD.

Post‑transplant lymphoproliferative disease
PTLD is a rare complication of HSCT (prevalance 0.5-1.5%) and in most cases associated with reactivation or primary Epstein-Barr virus (EBV) infection.[40] As stated earlier, most PTLD occurs within the first year post-transplantation, with the risk of development and onset of disease being directly proportional to the degree of immunosuppression. Hence, it is not surprising that the lymphoproliferative process may reversed on reduction or withdrawal of immunosuppression. This distinguishes PTLD from neoplastic lymphoproliferative disorders in immunocompetent patients. PTLD forms a continuum of three lesions: early lesions are non-malignant polyclonal B cell proliferation presenting as infectious mononucleosis-type acute illness, polymorphic PTLD consisting of malignant polyclonal or monoclonal lymphoid infiltrates that fall short of all criteria of lymphomas, and monomorphic PTLD consisting of malignant monoclonal lymphoid proliferation meeting all the criteria of B, T, or NK cell lymphomas. PTLD also occurs after solid organ transplantation, but differs from the post-HSCT setting in that it occurs later and is less aggressive.[41] Radiological features include generalized lymphadenopathy and solid organ involvement either diffusely or as focal masses and nodules like pulmonary nodules and liver masses [Figure 18]. Apart from reducing the extent of immnosuppression, it can be managed by using cytotoxic chemotherapy and rituximab. Locoregional treatment like surgery or radiation may also be useful.

Conclusion
Stem cell transplantation is a promising therapy for several chronic degenerative diseases, non-malignant conditions, and malignancies. The traditional approach of stem cell treatment has been the systemic use of hematopoietic stem cells in several hematological conditions like chronic anemias, metabolic conditions, lymphoma, and leukemia. However, such systemic stem cell therapy is limited by several complications in multiple organ systems primarily dependent on the immune status and type of HSCT. Allogenic transplant recipients are at risk for developing GVHD and its related complications, whereas autologous transplant recipients have higher risk of relapse with infections and late transplantation complications being less common. The role of imaging in systemic HSCT is primarily detection and narrowing the differential diagnosis in patients suspected to have post-transplant complications. It is possible to make an accurate diagnosis of HSCT complications on imaging if the radiologist has an understanding of the underlying immune-physiological processes and interprets studies in the light of such information.

Acknowledgement
The authors acknowledge Ms Donna Ashlock for help with Figure 1 in the manuscript.
References

1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010;303:1617-24.

2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:663-76.

3. Centeno CJ, Busse D, Koidis J, Keesman M, Harris M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain 2006;131:663-76.

4. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, et al. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 2012;10:3.

5. Jagannathan JP, Ramaiya N, Gill RR, Alyea EP, 3. Ros P. Imaging of complications of hematopoietic stem cell transplantation. Radiol Clin North Am 2008;46:397-417.

6. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273-84.

7. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest 1996;109:1066-77.

8. Escuissato DL, Gasparetto EL, Marchiori E, Rocha Gde M, Inoue C, Pasquini R, et al. Pulmonary infections after bone marrow transplantation: High-resolution CT findings in 111 patients. AJR Am J Roentgenol 2005;185:608-15.

9. Aronchick JM. Pulmonary infections in cancer and bone marrow transplant patients. Semin Roentgenol 2000;35:140-51.

10. Spitzer TR. Engraftment syndrome following hematopoietic cell transplantation. Bone Marrow Transplant 2001;27:893-9.

11. Wah TM, Moss HA, Robertson RJ, Barnett DL. Pulmonary complications following bone marrow transplantation. Br J Radiol 2003;76:373-9.

12. Patz EF Jr, Peters WP, Goodman PC. Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. J Thorac Imaging 1994;9:129-34.

13. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: High-resolution CT findings. AJR Am J Roentgenol 2000;175:1019-24.

14. Leather HL, Wingard JR. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am 2001;15:483-520.

15. Gasparetto EL, Ono SE, Escuissato D, Marchiori E, Roldan L, Marques HL, et al. Cytomegalovirus pneumonia after bone marrow transplantation: High resolution CT findings. Br J Radiol 2004;77:724-7.

16. Leung AN, Gosselin MV, Napper CH, Braun SG, Hu WW, Wong RM, et al. Pulmonary infections after bone marrow transplantation: Clinical and radiographic findings. Radiology 1999;210:699-710.

17. Kantrow SP, Hackman RC, Boekh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: Changing spectrum of lung injury after marrow transplantation. Transplantation 1997;63:1079-86.

18. Clark JC, Hansen IA, Hertz MI, Parkman R, Jensen L, Peavy HH. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147:1601-6.

19. Sampaio S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63:876-82.

20. Freudengerberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003;102:3822-4.

21. Mathew P, Bozeman P, Krance RA, Brenner MK, Heslop HE. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;13:221-3.

22. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002;11:215-29.

23. Ketelsen D, Vogel W, Bethge W, Werner M, Dietz K, Claussen CD, et al. Enlargement of the common bile duct in patients with acute graft-versus-host disease: What does it mean? AJR Am J Roentgenol 2009;193:W181-5.

24. Semelka RC, Kelekis NL, Sallah S, Worawattanakul S, Ascher SM. Hepatosplenic fungal disease: Diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol 1997;169:1311-6.

25. Metser U, Atri M, Lockwood G, Minden M. Fungal liver infection in immunocompromised patients: Depiction with multiphasic contrast-enhanced helical CT. Radiology 2005;235:97-105.

26. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003;78:589-98.

27. McDomin GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-67.

28. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver: High-resolution CT findings. AJR Am J Roentgenol 1999;210:699-710.

29. Hommeyer SC, Teefey SA, Jacobson AF, Higano CS, Bianco JA, Colacurcio C, et al. Venoocclusive disease of the liver: Prospective study of US evaluation. Radiology 1992;184:683-6.

30. Erturk S, Mortelé KJ, Binkert CA, Glickman JN, Oliva MR,
Ros PR, et al.: CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol 2006;186:1497-501.

31. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-14.

32. Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, et al. Prospective evaluation of acute graft-versus-host disease. Dig Dis Sci 2012;57:720-5.

33. Day DL, Ramsay NK, Letourneau JG. Pneumatosis intestinalis after bone marrow transplantation. AJR Am J Roentgenol 1988;151:85-7.

34. Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant 2002;29:509-13.

35. Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008;41:393-8.

36. Socié G, Cahn JY, Carmelo J, Vernant JP, Jouet JP, Ifrah N, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: Analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol 1997;97:865-70.

37. Stanzani M, Tumietto F, Giannini MB, Bianchi G, Nanetti A, Vianelli N, et al. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. J Med Microbiol 2007;56:1692-5.

38. Wellinghausen N, Moericke A, Bundschuh S, Friedrich W, Schulz AS, Gatz SA. Multifocal osteomyelitis caused by Candida dubliniensis. J Med Microbiol 2009;58:386-90.

39. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003;21:1352-8.

40. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003;31:145-55.

41. Burney K, Bradley M, Buckley A, Lyburn I, Rye A, Hopkins R. Posttransplant lymphoproliferative disorder: A pictorial review. Australas Radiol 2006;50:412-8.

Cite this article as: Pandey T, Maximin S, Bhargava P. Imaging of complications from hematopoietic stem cell transplant. Indian J Radiol Imaging 2014;24:327-38.

Source of Support: Nil, Conflict of Interest: None declared.